Nkarta, Inc.
NKTXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 11, 2026
4wMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
How NKTX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fludarabine, Cyclophosphamide | Phase 2 | Lupus Nephritis | - | - |
NKX019 | Phase 2 | Systemic Sclerosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Nkarta, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Nkarta, Inc.'s (NKTX) pipeline across Phase 2. Its lead program is Fludarabine, Cyclophosphamide (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nkarta, Inc.'s next FDA catalyst?→
Nkarta, Inc.'s (NKTX) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NKTX biotech catalysts?→
Add NKTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nkarta, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.